Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

Similar articles for PubMed (Select 24596047)

1.

Early treatment discontinuation and switching in first-line metastatic breast cancer: the role of patient-reported symptom burden.

Walker MS, Masaquel AS, Kerr J, Lalla D, Abidoye O, Houts AC, Schwartzberg LS.

Breast Cancer Res Treat. 2014 Apr;144(3):673-81. doi: 10.1007/s10549-014-2892-z. Epub 2014 Mar 5.

PMID:
24596047
3.

First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER.

Tripathy D, Kaufman PA, Brufsky AM, Mayer M, Yood MU, Yoo B, Quah C, Yardley D, Rugo HS.

Oncologist. 2013;18(5):501-10. doi: 10.1634/theoncologist.2012-0414. Epub 2013 May 7.

4.

The association of chemotherapy versus hormonal therapy and health outcomes among patients with hormone receptor-positive, HER2-negative metastatic breast cancer: experience from the patient perspective.

Gupta S, Zhang J, Jerusalem G.

Expert Rev Pharmacoecon Outcomes Res. 2014 Dec;14(6):929-40. doi: 10.1586/14737167.2014.949243. Epub 2014 Aug 18.

PMID:
25130198
5.

Patient and practice impact of capecitabine compared to taxanes in first-/second-line chemotherapy for metastatic breast cancer.

Schwartzberg LS, Cobb P, Walker MS, Stepanski EJ, Houts AC.

Support Care Cancer. 2009 Aug;17(8):1081-8. doi: 10.1007/s00520-008-0558-2. Epub 2009 Jan 13.

PMID:
19148686
6.

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.

Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O'Rourke L, Oliva C, Stein S, Pegram M.

J Clin Oncol. 2009 Nov 20;27(33):5538-46. doi: 10.1200/JCO.2009.23.3734. Epub 2009 Sep 28.

7.

Symptom burden & quality of life among patients receiving second-line treatment of metastatic colorectal cancer.

Walker MS, Pharm EY, Kerr J, Yim YM, Stepanski EJ, Schwartzberg LS.

BMC Res Notes. 2012 Jun 20;5:314. doi: 10.1186/1756-0500-5-314.

8.

Retrospective study of the effect of disease progression on patient reported outcomes in HER-2 negative metastatic breast cancer patients.

Walker MS, Hasan M, Yim YM, Yu E, Stepanski EJ, Schwartzberg LS.

Health Qual Life Outcomes. 2011 Jun 20;9:46. doi: 10.1186/1477-7525-9-46.

9.

Impact of complementary oral enzyme application on the postoperative treatment results of breast cancer patients--results of an epidemiological multicentre retrolective cohort study.

Beuth J, Ost B, Pakdaman A, Rethfeldt E, Bock PR, Hanisch J, Schneider B.

Cancer Chemother Pharmacol. 2001 Jul;47 Suppl:S45-54.

PMID:
11561873
10.

Health-related quality of life in early breast cancer.

Groenvold M.

Dan Med Bull. 2010 Sep;57(9):B4184.

PMID:
20816024
11.

Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.

Wagner AD, Thomssen C, Haerting J, Unverzagt S.

Cochrane Database Syst Rev. 2012 Jul 11;7:CD008941. doi: 10.1002/14651858.CD008941.pub2. Review.

PMID:
22786517
12.

Vinorelbine and capecitabine in anthracycline- and/or taxane-pretreated metastatic breast cancer: sequential or combinational?

Zhang J, Gu SY, Gan Y, Wang ZH, Wang BY, Guo HY, Wang JL, Wang LP, Zhao XM, Hu XC.

Cancer Chemother Pharmacol. 2013 Jan;71(1):103-13. doi: 10.1007/s00280-012-1983-y. Epub 2012 Oct 2.

PMID:
23053266
14.

Long-term follow-up of patients with metastatic breast cancer: results of a retrospective, single-center analysis from 2000 to 2005.

Geiger S, Cnossen JA, Horster S, DiGioia D, Heinemann V, Stemmler HJ.

Anticancer Drugs. 2011 Oct;22(9):933-9. doi: 10.1097/CAD.0b013e32834860af.

PMID:
21666437
15.

Final overall survival results and effect of prolonged (≥ 1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial.

Smith I, Pierga JY, Biganzoli L, Cortes-Funes H, Thomssen C, Saracchini S, Nisenbaum B, Pelaez I, Duenne AA, Pritchard KI.

Breast Cancer Res Treat. 2011 Nov;130(1):133-43. doi: 10.1007/s10549-011-1695-8. Epub 2011 Aug 10.

PMID:
21830015
16.

Impact of symptom burden on work-related abilities in patients with locally recurrent or metastatic breast cancer: Results from a substudy of the VIRGO observational cohort study.

Cleeland CS, Mayer M, Dreyer NA, Yim YM, Yu E, Su Z, Mun Y, Sloan JA, Kaufman PA.

Breast. 2014 Dec;23(6):763-9. doi: 10.1016/j.breast.2014.08.004. Epub 2014 Sep 3.

PMID:
25193423
17.

[Clinical value of trastuzumab in the treatment of lapatinib-resistant HER2-positive metastatic breast cancer].

Ma F, Xu BH, Li HH, Li Q, Zhang P, Yuan P, Wang JY, Fan Y, Li Q.

Zhonghua Zhong Liu Za Zhi. 2013 Jul;35(7):521-4. Chinese.

PMID:
24257305
18.

Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.

Arslan UY, Turker I, Aksoy S, Oksuzoglu B, Helvaci K, Yildirim Ozdemir N, Uyeturk U, Uysal Sonmez O, Budakoglu B, Zengin N.

J BUON. 2013 Jul-Sep;18(3):585-93.

PMID:
24065468
19.

Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer.

Kamal AH, Camacho F, Anderson R, Wei W, Balkrishnan R, Kimmick G.

Breast Cancer Res Treat. 2012 Jul;134(1):371-8. doi: 10.1007/s10549-012-2037-1. Epub 2012 Mar 31.

PMID:
22460617
20.

Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer.

Cristofanilli M, Valero V, Mangalik A, Royce M, Rabinowitz I, Arena FP, Kroener JF, Curcio E, Watkins C, Bacus S, Cora EM, Anderson E, Magill PJ.

Clin Cancer Res. 2010 Mar 15;16(6):1904-14. doi: 10.1158/1078-0432.CCR-09-2282. Epub 2010 Mar 9.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk